Development of outcome measures for autoimmune dermatoses.

Development of outcome measures for autoimmune dermatoses. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Development of outcome measures for autoimmune dermatoses. Abstract Text:

Elizabeth Gaines,Victoria P Werth,Elizabeth Gaines,Victoria P Werth,

Validated outcome measures are essential in monitoring disease severity. Specifically in dermatology, which relies heavily on the clinical evaluation of the patient and not on laboratory values and radiographic tests, outcome measures help standardize patient care. Validated cutaneous scoring systems, much like standardized laboratory values, facilitate disease management and follow therapeutic response. Several cutaneous autoimmune dermatoses, specifically cutaneous lupus erythematosus (CLE), dermatomyositis (DM), and pemphigus vulgaris (PV), lack such outcome measures. As a result, evaluation of disease severity and patients' response to therapy over time is less reliable. Ultimately, patient care is compromised. These diseases, which are often chronic and relapsing and remitting, are also often refractory to treatment. Without outcome measures, new therapies cannot be systematically assessed in these diseases. Clinical trials that are completed without standardized outcome measures produce less reliable results. Therefore, the development of validated outcome measures in these autoimmune dermatoses is critical. However, the process of developing these tools is as important, if not more so, than their availability. This review examines the steps that should be considered when developing outcome measures, while further examining their importance in clinical practice and trials. Finally, this review more closely looks at CLE, DM, and PV and addresses the recent and ongoing progress that has been made in the development of their outcome measures.

Development of outcome measures for autoimmune dermatoses. Publishing Authors By Initials

E Gaines,VP Werth,E Gaines,VP Werth,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Development of outcome measures for autoimmune dermatoses. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatological research

VOLUME: 300

Page Numbers: 3-9

Journal Abbreviation: Arch. Dermatol. Res.

ISSN: 0340-3696

DAY: 6

MONTH: 11

YEAR: 2007

Development of outcome measures for autoimmune dermatoses. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8000462

Development of outcome measures for autoimmune dermatoses. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Development of outcome measures for autoimmune dermatoses. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Development of outcome measures for autoimmune dermatoses.

AFFILIATION: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Development of outcome measures for autoimmune dermatoses Related Publications

• Activation of autoimmunity following use of immunostimulatory herbal supplements.
• CONTINUING EDUCATION: Is It Valid?
• Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
• Cutaneous lupus: insights into pathogenesis and disease classification.
• Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
• Dermatologic therapeutics: thalidomide. A practical guide.
• Dermatology vignette. Pseudoporphyria caused by NSAIDs.
• Development of outcome measures for autoimmune dermatoses.
• Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus erythematosus: implications for phototesting.
• Lizard ecology: evidence of competition.
• Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center.
• Numerous erythematous truncal plaques. Multiple basal cell carcinomas associated with arsenic ingestion.
• Pathophysiology of cutaneous lupus erythematosus.
• RISK MANAGEMENT FOR CHIROPRACTORS AND OSTEOPATHS: Neck Manipulation & Vertebrobasilar Stroke.
• Regeneration of sulfur-fouled bimetallic Pd-based catalysts.
• Reliability of fMRI during a Continuous Motor Task: Assessment of Analysis Techniques.
• Risk Management for Chiropractors and Osteopaths. Informed consent: A Common Law Requirement.
• Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions.
• The cutaneous lupus erythematosus disease activity and severity index: Expansion for rheumatology and dermatology.
• The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
• Treatment of bullous pemphigoid with topical corticosteroids: review of a randomized controlled trial.
• Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
• Ulcerating skin lesions and arthritis after a crab bite.
• What is new in the treatment of steroid-induced osteoporosis?
• What is new in the treatment of steroid-induced osteoporosis?
• [Effect of malachite green on metabolism, especially on the enzymes of the respiratory chain in rats and their relation to the problem of abnormalities and carcinogenesis.]
• [Incidence of hereditary disorders caused by prolonged malachite green poisoning in rats; a contribution to chemogenesis.]
• [Methods of experimental research on cancer and its significance in practical medicine.]
• [The effect of malachite green on the growth of Walker rat carcinoma and Ehrlich mouse ascites tumor.]
• [The history of medicine. Richard Werth (1850-1918)]